Spectranetics Completes Acquisition of AngioScore
By HospiMedica International staff writers Posted on 13 Jul 2014 |
Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons.
The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated, complementary product lines. The acquisition will diversify Spectranetics’ current product portfolio, which includes a range of ablation laser catheters, support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices. The company also markets a lead management product line that includes excimer laser sheaths, dilator sheaths, mechanical sheaths, and accessories for the removal of pacemaker and defibrillator cardiac leads.
The acquisition will expand physicians’ options for treating critical limb ischemia (CLI), in‐stent restenosis (ISR), calcified lesions, and chronic total occlusions (CTO). Strategically, the combined company will expand Spectranetics’ addressable markets, broaden the product pipeline (including the addition of a proprietary drug‐coated scoring balloon platform), enhance and leverage Spectranetics’ strong sales and marketing capabilities, and drive significant operating efficiencies and savings.
“We are very excited to complete this important transaction. AngioScore meets our criteria with an exceptional strategic fit, leverageable call points, differentiated technology and clear operating efficiencies,” said Scott Drake, President and CEO of Spectranetics. “With AngioScore now a part of our company, we have a meaningfully expanded market opportunity and a compelling product portfolio.”
“Simply put, we are ‘better together.’ We believe that this combination provides an opportunity to build a remarkable future while delivering life‐impacting technologies to physicians and patients,” said Thomas R. Trotter, President and CEO of AngioScore. “In Spectranetics, we find a like‐minded partner that shares our values, our commitment to improving patients’ lives, and equally high standards for operational excellence and quality.”
Related Links:
Spectranetics
AngioScore
The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated, complementary product lines. The acquisition will diversify Spectranetics’ current product portfolio, which includes a range of ablation laser catheters, support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices. The company also markets a lead management product line that includes excimer laser sheaths, dilator sheaths, mechanical sheaths, and accessories for the removal of pacemaker and defibrillator cardiac leads.
The acquisition will expand physicians’ options for treating critical limb ischemia (CLI), in‐stent restenosis (ISR), calcified lesions, and chronic total occlusions (CTO). Strategically, the combined company will expand Spectranetics’ addressable markets, broaden the product pipeline (including the addition of a proprietary drug‐coated scoring balloon platform), enhance and leverage Spectranetics’ strong sales and marketing capabilities, and drive significant operating efficiencies and savings.
“We are very excited to complete this important transaction. AngioScore meets our criteria with an exceptional strategic fit, leverageable call points, differentiated technology and clear operating efficiencies,” said Scott Drake, President and CEO of Spectranetics. “With AngioScore now a part of our company, we have a meaningfully expanded market opportunity and a compelling product portfolio.”
“Simply put, we are ‘better together.’ We believe that this combination provides an opportunity to build a remarkable future while delivering life‐impacting technologies to physicians and patients,” said Thomas R. Trotter, President and CEO of AngioScore. “In Spectranetics, we find a like‐minded partner that shares our values, our commitment to improving patients’ lives, and equally high standards for operational excellence and quality.”
Related Links:
Spectranetics
AngioScore
Latest Business News
- Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
- Mindray to Acquire Chinese Medical Device Company APT Medical
- Olympus Acquires Korean GI Stent Maker Taewoong Medical
- Karl Storz Acquires British AI Specialist Innersight Labs
- Stryker to Acquire French Joint Replacement Company SERF SAS
- Medical Illumination Acquires Surgical Lighting Specialist Isolux
- 5G Remote-Controlled Robots to Enable Even Cross-Border Surgeries
- International Hospital Federation Announces 2023 IHF Award Winners
- Unprecedented AI Integration Transforming Surgery Landscape, Say Experts
- New WHO Guidelines to Revolutionize AI in Healthcare
- Getinge Acquires US-Based Medical Equipment Provider Healthmark Industries
- Global Surgical Lights Market Driven by Increasing Number of Procedures
- Global Capsule Endoscopy Market Driven by Demand for Accurate Diagnosis of Gastrointestinal Conditions
- Global OR Integration Market Driven by Need for Improved Workflow Efficiency and Productivity
- Global Endoscopy Devices Market Driven by Increasing Adoption of Endoscopes in Surgical Procedures
- Global Minimally Invasive Medical Devices Market Driven by Benefits of MIS Procedures